Innovative approach for improved rFVIII concentrate

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 361-368

  Morfini, Massimo ^a  

^a University Hospital   (Italy)

Author keywords

Haemophilia A; Inhibitor; Recombinant factor VIII; Safety; Turoctocog alfa

Indexed keywords

BLOOD CLOTTING FACTOR 8; PHARMACOLOGICAL BIOMARKER; RECOMBINANT FACTOR VIII N8; RECOMBINANT PROTEIN; SULFATE;

ANIMAL; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; DRUG INDUSTRY; GENE EXPRESSION; GENETICS; GLYCOSYLATION; HEMOPHILIA A; HUMAN; ISOLATION AND PURIFICATION; PRACTICE GUIDELINE; PROTEIN PROCESSING;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CHO CELLS; CRICETULUS; DRUG INDUSTRY; FACTOR VIII; GENE EXPRESSION; GLYCOSYLATION; HEMOPHILIA A; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SULFATES;

EID: 84911484405     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12359     Document Type: Review

References (65)

1. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004;18:1-15.
2. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for haemophilia. Hematology Am Soc Hematol Educ Program 2013;2013:30-6.
3. Lane S. Haemorrhagic diathesis: successful transfusion of blood. Lancet 1840;41:185-8.
4. Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics - from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem 2002;35(Pt 2):141-8.
5. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110:815-25.
6. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001;66:229-40.
7. Hilgartner M. AIDS in the transfusion recipient. Pediatr Clin North Am 1991;38:121-31.
8. Knight R, Stanley S, Wong M, Dolan G. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost 2006;32(Suppl 2):3-9.
9. Josephson N. The hemophilia's and their clinical management. Hematology Am Soc Hematol Educ Program 2013;2013:261-7.
10. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, Hill FG, Hay CR; UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004;2:1047-54.
11. Fransen van de Putte DE, Fischer K, Pulles AE, Roosendaal G, Biesma DH, Schutgens RE, Mauser-Bunschoten EP. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res 2012;130:157-62.
12. Schaub RG. Recent advances in the development of coagulation factors and BN procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011;82:91-8.
13. Santagostino E, Mancuso ME. Venous access in hemophilic children: choice and management. Haemophilia 2010;16(Suppl 1):20-4.
14. Orlova NA, Kovnir SV, Vorobiev II, Gabibov AG, Vorobiev AI. Blood clotting factor VIII: from evolution to therapy. Acta Naturae 2013;5:19-39.
15. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J 2008;3:90-7.
16. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007;370:439-48.
17. Ljung R, Auerswald G, Benson G, Jetter A, Jiménez-Yuste V, Lambert T, Morfini M, Remor E, Sørensen B, Salek SZ. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013;19:481-6.
18. ®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011;17:854-9.
19. Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci 2009;98:4480-4.
20. Vazquez E, Corchero JL, Villaverde A. Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact 2011;10:60.
21. Kannicht C, Ramström M, Kohla G, Tiemeyer M, Casademunt E, Walter O, Sandberg H. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013;131:78-88.
22. Zhu J, Wooh JW, Hou JJ, Hughes BS, Gray PP, Munro TP. Recombinant human albumin supports single cell cloning of CHO cells in chemically defined media. Biotechnol Prog 2012;28:887-91.
23. Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 2012;93:917-30.
24. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Hemophilia 2010;16:349-59.
25. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998;4:558-63.
26. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007;109:610-2.
27. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconj J 2009;26:231-45.
28. Diaz SL, Padler-Karavani V, Ghaderi D, Hurtado-Ziola N, Yu H, Chen X, Brinkman-Van der Linden EC, Varki A, Varki NM. Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS ONE 2009;4:e4241.
29. Schilow WF, Schoerner-Burkhardt E, Seitz R. Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards. Thromb Haemost 2004;92:427-8.
30. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368:231-9.
31. Butler M, Meneses-Acosta A. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl Microbiol Biotechnol 2012;96:885-94.
32. Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2004;2:1380-4.
33. Lambert KJ, Birch JR. Cell growth media. In: Spier RE, Griffiths JB, eds. Animal Cell Biotechnology. Volume 1, London: Academic Press; 1985: 85-122.
34. Omasa T, Onitsuka M, Kim WD. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr Pharm Biotechnol 2010;11:233-40.
35. Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010;16:878-87.
36. Aygören-Pürsün E, Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost 1997;78:1352-6.
37. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011;38:65-70.
38. Nims RW, Gauvin G, Plavsic M. Gamma irradiation of animal sera for inactivation of viruses and mollicutes - a review. Biologicals 2011;39:370-7.
39. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012;52:1482-9.
40. Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006;367:252-61.
41. Glynn SA, Busch MP, Dodd RY, Katz LM, Stramer SL, Klein HG, Simmons G, Kleinman SH, Shurin SB, NHLBI Emerging Infectious Disease Task Force convened November 7, 2011. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013;53:438-54.
42. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010;16:296-304.
43. Millar CM, Makris M. Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products. Br J Haematol 2012;158:442-52.
44. Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, Sisó S, González L, Jeffrey M, Hunter N. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008;112:4739-45.
45. Parchi P, Saverioni D. Molecular pathology, classification, and diagnosis of sporadic human prion disease variants. Folia Neuropathol 2012;50:20-45.
46. Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion 2013;53:1217-25.
47. Eis-Hübinger AM, Matz B, Effenberger W, Brackmann HH, Neipel F. Human herpesvirus 8 infection in haemophiliacs. Thromb Haemost 2000;84:515-7.
48. Theodossiades G, Arvanitakis L, Tsevrenis V, Nomikou E, Zografidis A, Bourboulia D, Kontopoulou-Griva I. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in haemophilic patients. Haemophilia 2003;9:657-9.
49. Azzi A, De Santis R, Morfini M, Zakrzewska K, Musso R, Santagostino E, Castaman G. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood 2001;98:2571-3.
50. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009;4:186-201.
51. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. Nature 2005;437:257-61.
52. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013;347:f5675.
53. Béringue V, Herzog L, Jaumain E, Reine F, Sibille P, Le Dur A, Vilotte JL, Laude H. Facilitated cross-species transmission of prions in extraneural tissue. Science 2012;335:472-5.
54. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006;35:83-90.
55. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003;9:24-37.
56. Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, Wakisaka A, Tanifuji M, Tomono T. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process. Vox Sang 2006;91:119-25.
57. Grein TA, Michalsky R, Czermak P. Virus separation using membranes. Methods Mol Biol 2014;1104:459-91.
58. Saxena A, Tripathi BP, Kumar M, Shahi VK. Membrane-based techniques for the separation and purification of proteins: an overview. Adv Colloid Interface Sci 2009;145:1-22.
59. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013;27:179-84.
60. ™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013;19:691-7.
61. ™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe hemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013;19:698-705.
62. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013;11(Suppl 1):84-98.
63. Agersø H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GPin hemophilia A dogs. Haemophilia 2012;18:941-7.
64. Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domainO-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013;121:2108-16.
65. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11:670-8.